MicroRNAs have gained popularity as a potential treatment for many diseases, including
stroke. This study identifies and characterizes a specific member of the miR-17-92 cluster, miR-20a-3p, as a possible
stroke therapeutic. A comprehensive
microRNA screening showed that miR-20a-3p was significantly upregulated in astrocytes of adult female rats, which typically have better
stroke outcomes, while it was profoundly downregulated in astrocytes of middle-aged females and adult and middle-aged males, groups that typically have more severe
stroke outcomes. Assays using primary human astrocytes and neurons show that miR-20a-3p treatment alters mitochondrial dynamics in both cell types. To assess whether
stroke outcomes could be improved by elevating astrocytic miR-20a-3p, we created a
tetracycline (Tet)-induced recombinant adeno-associated virus (rAAV) construct where miR-20a-3p was located downstream a
glial fibrillary acidic protein promoter. Treatment with
doxycycline induced miR-20-3p expression in astrocytes, reducing mortality and modestly improving sensory motor behavior. A second Tet-induced rAAV construct was created in which miR-20a-3p was located downstream of a
neuron-specific enolase (NSE) promoter. These experiments demonstrate that neuronal expression of miR-20a-3p is vastly more neuroprotective than astrocytic expression, with animals receiving the miR-20a-3p vector showing reduced
infarction and sensory motor improvement.
Intravenous injections, which are a therapeutically tractable treatment route, with miR-20a-3p mimic 4 h after
middle cerebral artery occlusion (MCAo) significantly improved
stroke outcomes including
infarct volume and sensory motor performance. Improvement was not observed when miR-20a-3p was given immediately or 24 h after MCAo, identifying a unique delayed therapeutic window. Overall, this study identifies a novel neuroprotective
microRNA and characterizes several key pathways by which it can improve
stroke outcomes.